Mozart is a biotech startup focusing on the development of disease-modifying therapies for autoimmune and inflammatory diseases.
Mozart Therapeutics has raised $25.0M in total funding. The most recent round was Series A. The last funding was announced in June 2023.
Mozart Therapeutics's investors include ARCH Venture Partners, Eli Lilly, AbbVie, Sofinnova Partners, Pfizer Venture Investments.
Mozart Therapeutics is headquartered in Seattle, United States.
Mozart is a biotech startup focusing on the development of disease-modifying therapies for autoimmune and inflammatory diseases.
Mozart Therapeutics is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Mozart Therapeutics — Funding & Investors." VCBacked, June 7, 2023, https://www.vcbacked.co/company/mozart-therapeutics. Accessed July 19, 2026.
VCBacked. (2023). Mozart Therapeutics — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/mozart-therapeutics
{{cite web |title=Mozart Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/mozart-therapeutics |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated